Indiana Gov. signs law on biosimilar substitution
Indiana Governor Mike Pence this week signed Senate Bill 262, a bill on biosimilar drugs that allows substitution if certain conditions are met.
European survey highlights gaps in knowledge of biosimilars
The Alliance for Safe Biologics and EuropaBio recently released results of a survey of 470 European physicians’ views on biosimilar naming.
Will Cuts to Medicare Advantage Put America’s Seniors at a Disadvantage?
Cuts mandated by the Affordable Care Act could cause 4.8 million seniors to lose or drop their Medicare Advantage coverage, predicts the Congressional Budget Office.
Advocates Unite on FDA-Approved Therapies for Pregnant Women
Pregnant women constitute a highly sensitive population when it comes to medical therapies.
Patient Advocates Hail Synchronization as Commonsense Tool
Patients with chronic conditions may undermine their own wellness by straying from their physicians’ instructions.
Coverage for Obesity Treatments Could Lower Long-term Costs
Medicaid coverage for obesity treatments could save money over the long term, suggests a new policy brief from the Institute for Patient Access.
Headache Patients Face Limited Options, Despite Prevalence and Pain
Far more than an occasional nuisance, headaches interfere with countless Americans’ daily lives – and cost the country $31 billion annually.
Biologic Therapy Substitution to be Considered by World Health Assembly
Recently two World Health Organization resolutions were approved for consideration at the 67th World Health Assembly, to convene this coming May in Geneva.
340B Controversy Jeopardizes Patient Access
When big hospitals profit by gaming a government program, public confidence wanes – and patient access could suffer.
High Co-Pays Inhibit Access for Cancer Patients
You can’t put a price on health, the saying goes. But for certain leukemia patients who need protein kinase inhibitor treatment, cost can prove to be not only a key factor but also a barrier to wellness.
